Archives

Loading Events

Hyperuricemia In CKD & Specific Considerations In ADPKD

Hyperuricemia In CKD & Specific Considerations In ADPKD

Background

Hyperuricemia is frequently associated with a number of other conditions such as hypertension, type 2 diabetes, obesity, heart failure, overweight, and cardiovascular disease. In CKD, the CV mortality is increased with inflammatory gout and inflammatory processes involving uric acid contributing to CKD.

Did You Know?

  • Did you know that over 50%1 of dialysis patients present with hyperuricemia?
Why Attend This Webinar?
  • To expand your understanding of hyperuricemia and its impact on CKD and ADPKD patients. As well as discuss some of the controversies around treatment modalities.
What You Will Learn
  • This webinar will cover biochemistry and physiology of uric acid and its pathway
  • Will also discuss the pathophysiology of uric acid in gout, CKD, and ADPKD
  • Discuss therapeutic options and the current controversies around them
References:
  1. Piani F. et al. Hyperuricemia and chronic kidney disease: to treat or not to treat, https://doi.org/10.1590/2175-8239-JBN-2020-U002 Accessed October 2022.

Featuring

Ramy M. Hanna

Ramy M. Hanna, MD

Associate Clinical Professor of Medicine and Nephrology

University of California Irvine UCI-Health*

Dr Hanna is an Associate Clinical Professor of Medicine and Nephrology at the University of California Irvine UCI-Health. He is as a clinician-educator working on reporting of anti vegf agent toxicity (systemic, and intravitreal). He is also interested in AHUS and TMA treatment and clinical outcomes, as well as cases of C3 GN and novel outcomes with C5 and C3 complement blockade. He has done prior work on dysnatremias and sodium correction modeling, as well as optimization of vaptan clinical response. Glomerular disease is also a key area of interest, with case reports written up when evidence of novel pathology or interest is found. He is generally familiar with onco-nephrology. As far as Clinical interests GNs, care of underserved populations are his niche areas.

Rim Hadgu

Rim Hadgu, PharmD, BCPS

Nephrology Clinical & Scientific Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Dr Rim Hadgu is a Nephrology Clinical and Scientific Liaison at Otsuka Pharmaceutical Development and Commercialization. She obtained her Doctor of Pharmacy degree from St. Louis College of Pharmacy. She completed an American Society of Health-System Pharmacists (ASHP)-Accredited PGY1 Pharmacy Residency at Xavier University of Louisiana College of Pharmacy and University Medical Center New Orleans. She also completed an ASHP-Accredited PGY2 Nephrology Pharmacy Residency at Albany College of Pharmacy and Health Sciences. Prior to joining Otsuka in October 2021, she was an Assistant Professor of Pharmacy Practice at Midwestern University College of Pharmacy, Glendale Campus where she delivered lectures, precepted Advanced Pharmacy Practice Experience students as well as PGY1 and PGY2 pharmacy residents. She also practiced as a nephrology clinical pharmacist for two years. Dr Hadgu is a Board Certified Pharmacotherapy Specialist by the Board of Pharmacy Specialties.

*Dr Hanna is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Hagdu is an employee of OPDC.

Registration

Related Resources